Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-25T13:59:20.987Z Has data issue: false hasContentIssue false
  • English
  • Français

Azathioprine in Myeloproliferative and Autoimmune Disorders

Published online by Cambridge University Press:  01 August 2014

D. Taglioretti  and
A. Giangrande
D. Taglioretti
Affiliation:
Istituto di Clinica Medica Generale e Terapia dell'Università, Milano
A. Giangrande
Affiliation:
Istituto di Clinica Medica Generale e Terapia dell'Università, Milano

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The report presents the clinical results of treatment with Azathioprine 6 [(methyl-4-nitro-5-imidazolyl) thio] purine, in patients with acute leukaemia, the acute relapsing phase of chronic myelocytic leukaemia and in a group of patients affected by illness which have probably an autoimmune pathogenesis.

Favorable results were obtained in the group of patients suffering from acute leukaemia with a percentage of clinical and/or haematological remission of 57%.

A comparative analysis of the length of survival in these patients compared to that of a similar group of patients treated with 6-mercaptopurine is also reported.

A fair response was also obtained in the group of patients in the acute relapsing phase of C.M.L.

In the group of patients affected by diseases probably due to an immune pathogenesis, a favorable response was obtained in 2 cases of systemic lupus erithematosus with haemolytic anaemia and 1 case of acquired autoimmune haemolytic anaemia.

Type
Research Article
Information
Acta geneticae medicae et gemellologiae: twin research , Volume 17 , Issue 1 , January 1968 , pp. 258 - 269
Copyright
Copyright © The International Society for Twin Studies 1968

References

Bollag, W. (1963). Suppression of the immunological reaction by methylhydrazine, a new class of antitumor agents. Experientia, 19: 304.Google Scholar
Bowen, G. E. et al. (1966). Early esperiences with azathioprine in ulcerative eolitis. A note of caution. J.A.M.A., 195: 460.Google Scholar
Bresnik, E., (1959). The metabolism in vitro of antitumour Imidazolyl derivatives of Mercaptopurines. Fed. Proc., 18: 371.Google Scholar
Calne, R. Y., Murray, D. E. (1961). Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant. Bull., 26: 445.Google Scholar
Clarke, D. A. et al. (1958). Structure-activity relationships amoung purines related to 6-mercaptopurine. Cancer Rep., 18: 445.Google Scholar
Demis, D. J. et al. (1964). Thioguanine in the treatment of certain autoimmune, immunologic and related diseases. Amer. J. Med., 37: 195.Google Scholar
Elion, G. E. et al. (1961). A summary of investigations with 6-[(1-methyl-4-nitro-5-imidazolyl)thio] purine (B.W. 57-322). Cancer Chemother. Rep., 14: 93.Google Scholar
Elves, M. W. et al. (1963). The response of lymphocytes to antigen challenge in vitro. Lancet, 1: 806.Google Scholar
Gehan, E. A. (1960). Use of medical measurement to predict the course of disease. Nat. Cancer Inst. Monogr., 3: 51.Google Scholar
Hirschhorn, K. et al. (1963). Immune response and mitosis of human peripheral blood lymphocytes in vitro. Science, 142: 1185.Google Scholar
Hitchings, G. M., Elion, G. B. (1963). Chemical suppression of the immune response. Pharmacol. Rev., 15: 365.Google Scholar
Levin, R. H. et al. (1964). The effect of 6-mercaptopurine on immune response in man. New. Engl. J. Med., 271: 16.Google Scholar
Lorenzen, I., Videbaek, A. (1965). Treatment of collagen diseases with cytostatics. Lancet, 2: 558.Google Scholar
Mac Kay, I. R., Wood, I. J. (1963). The course and treatment of lupoid hepatitis. Gastroenterology, 45: 4.Google Scholar
Richmond, J. et al. (1963). A case of idiopathic thrombocytopenia and autoimmune haemolytic anaemia treated by thymic irradiation and by administration of Imuran and Actinomycin C. Lancet 2: 125.Google Scholar
Rundles, R. W. et al. (1961). Clinical and hematologic study of 6-[(1-methyl-4-nitro-5-imidazolyl) thio] purine (B.W.57-322) and related compounds. Cancer Chemother. Rep., 14: 99.Google Scholar